Melzi joined the Zimmer in 1990 as managing director and was promoted to chairman of Europe, Middle East and Africa in 2003. Previously, he worked at Johnson & Johnson (NYSE:JNJ). Italy and Smith & Nephew (FTSE:SN, NYSE:SNN) Italy.
Zimmer will pay Melzi 75,000 Euros and additional compensation as of March 31, according to the regulatory filing.
Melzi signed post-retirement directorship agreement, in which he will receive 355,920 Euros annually as the director of some of the company’s European subsidiaries. Under the 3 year agreement, he will work 4 days a week to help the transition of executive leadership responsibilities for Zimmer’s EMEA region, beginning March 31.
JenaValve has named Raymond Cohen executive chairman of its board of directors.
Cowles most recently was CEO of privately-held Laguna Hills, CA-based Vessix Vascular, which develops percutaneous RF balloon catheter renal denervation system to treat uncontrolled hypertension. Boston Scientific (NYSE:BSX) last November acquired Vessix for $425 million.
San Diego, Calif.-based DexCom added COO duties to its president Kevin Sayer’s title.
Sayer will continue working for the Company’s R&D, manufacturing, clinical, regulatory and finance functions, as well as leading DexCom’s sales, marketing, and other core commercial functions, according to the regulatory filing.
SurModicswelcomes new CFO
SurModics named Andy LaFrence as the company’s VP of finance & CFO,effective February 12.
BioVentrix named Noel Messenger the company’s vice president of regulatory & clinical affairs.
Messenger most recently worked at Santa Clara, Calif.-based Guided Delivery Systems as vice president of regulatory affairs & quality assurance, prior to which, he worked at TriVascular.